All plots were generated in GraphPad PRISM
Still, some early clinical findings hint at potential uses in more specific contexts: Perioperative brain protection: A randomized controlled trial involving 155 liver surgery patients found that ALA reduced oxidative brain injury from anesthesia (sevoflurane) and improved cognitive recovery scores after surgery.31 Neurodegenerative conditions: In a small trial, ALA appeared to slow brain atrophy in patients with secondary progressive multiple sclerosis over a two-year period.32 While promising, this outcome still needs further confirmation
Fisetin is often combined with quercetin for complementary senolytic effects
Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
